NervGen Pharma Corp.
NGEN.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.81% | -19.44% | -61.34% | 50.03% | -44.58% |
| Total Depreciation and Amortization | -60.21% | -60.81% | -57.85% | 10.51% | 10.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.54% | -101.67% | 36.66% | -223.60% | 3,034.46% |
| Change in Net Operating Assets | 146.06% | -921.27% | -2.66% | 117.33% | -71.51% |
| Cash from Operations | -15.25% | -295.86% | -105.36% | 31.87% | 39.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 118.28% | -- | -- | -- |
| Cash from Investing | -- | 117.93% | 377.27% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 235.20% | 202.25% | -41.24% | 5,951.78% | -57.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 302.73% | 266.30% | -56.98% | 5,942.54% | -6.30% |
| Foreign Exchange rate Adjustments | -253.09% | -146.45% | 262.94% | -588.43% | 58.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.30% | -320.86% | -89.58% | 522.22% | 40.57% |